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One of the major limitations in studying membrane pro-
teins has been the general difficulty in producing significant 
quantities of correctly folded protein. The present invention 
addresses this need. 
5 
Relevant Literature 
Protein synthesis is a fundamental biological process that 
underlies the development of polypeptide therapeutics, diag-
nostics, and industrial enzymes. With the advent of recombi-
nant DNA (rDNA) technology, it has become possible to 
harness the catalytic machinery of the cell to produce a 
desired protein. This can be achieved within the cellular envi-
ronment or in vitro using extracts derived from cells. 
Cell-free protein synthesis offers several advantages over 
in vivo protein expression methods. Cell-free systems can 
direct most, if not all, of the metabolic resources of the cell 
towards the exclusive production of one protein. Moreover, 
the lack of a cell wall in vitro is advantageous since it allows 
for control of the synthesis environment. For example, tRNA 
levels can be changed to reflect the codon usage of genes 
being expressed. The redox potential, pH, or ionic strength 
can also be altered with greater flexibility than in vivo since 
we are not concerned about cell growth or viability. Further-
more, direct recovery of purified, properly folded protein 
products can be easily achieved. 
In vitro translation is also recognized for its ability to 
incorporate unnatural and isotope-labeled amino acids as 
well as its capability to produce proteins that are unstable, 
insoluble, or cytotoxic in vivo. In addition, cell-free protein 
synthesis may play a role in revolutionizing protein engineer-
ing and proteomic screening technologies. The cell-free 
method bypasses the laborious processes required for cloning 
and transforming cells for the expression of new gene prod-
ucts in vivo, and is becoming a platform technology for this 
field. 
Among the proteins of interest for cell-free synthesis, 
many either span or are anchored to membranes. These pro-
teins and other biomolecules incorporated into membranes 
surrounding cells and organelles moderate a wide variety of 
cellular functions. Furthermore, many lipids and glycolipids 
are targets for, or activate, protein functions. 
For example, about half of potential pharmaceutical targets 
are membrane proteins, e.g. ion channels and G protein 
coupled receptors, which have been difficult to utilize in drug 
screening and design assays. Because of their location in 
membranes, these proteins are frequently difficult to purify 
and characterize. They are also difficult to obtain in large 
quantities, and recombinant DNA methods often fail to pro-
vide large amounts of properly folded membrane proteins, in 
part because overexpression of membrane proteins is gener-
ally toxic to living cells, thus limiting the yield. 
To avoid this toxicity, in vitro techniques have been 
attempted to produce higher yields of protein. However, 
reports have shown either low yields, similar or less than 
those obtained in vivo; high yields, but where most of the 
protein is aggregated and must be refolded post-translation-
ally; or high yields where the protein has been synthesized 
into detergents or lipo somes without using the natural folding 
pathway, raising a question of whether these systems produce 
membrane proteins that are authentically folded. 
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SUMMARY OF THE INVENTION 
25 	 Methods are provided for high yield cell-free synthesis of 
membrane associated proteins. In the methods of the inven-
tion, vesicles are added to a cell-free synthesis reaction, pro-
viding for direct insertion of the nascent polypeptide into a 
biological membrane, thereby providing for folding in a 
30 membrane environment. Generally the synthesis is per-
formed as a coupled transcription and translation reaction to 
allow for co-translational folding. These methods provide for 
high yields of active protein. The method may further include 
the isolation of the synthesized protein in a membrane bound 
35 state. 
In some embodiments, the methods of the invention further 
include providing signal recognition particles (SRP) to the 
reaction. The particles may be exogenously produced, or 
co-synthesized in the reaction mix. A docking protein for the 
40 SRP may also be included. 
In a preferred embodiment, the synthesis reaction condi-
tions provide for in vitro activation of oxidative phosphory-
lation. The activation of oxidative phosphorylation may be 
evidenced by the ability of the reaction mixture to regenerate 
45 ATP in the absence of conventional secondary energy 
sources. The activation of oxidative phosphorylation can also 
be demonstrated by the sensitivity of the reaction mixture to 
specific inhibitors of this pathway. Such reactions are sub-
stantially free of polyethylene glycol. 
50 	 Production of high yields of active membrane associated 
proteins is useful in a variety of methods, including screening 
for drug candidates that interact with pharmacologically rel-
evant membrane protein targets such as multi-drug transport-
ers or signaling proteins; development of membrane protein- 
55 based biosensors; strategies for detoxification wherein the 
vesicles import toxins for subsequent vesicle recovery and 
removal; and the like. 
BRIEF DESCRIPTION OF THE DRAWINGS 
60 
FIG. 1 Total and dialyzed protein yields from cell-free 
reactions synthesizing MtIA or TetA. 
FIG. 2(a) Topology of MtIA showing six transmembrane 
segments and a large C-terminal domain on the cytoplasmic 
65 side of the membrane. (b) Predicted topology of the trans-
membrane portion of MtIA. The largest cytoplasmic loop 
(K185-V273) encompasses 89 amino acids. 
CELL-FREE SYNTHESIS OF MEMBRANE 
BOUND POLYPEPTIDES 
FEDERALLY SPONSORED RESEARCH AND 
DEVELOPMENT 
This invention was made with Government support under 
contract NAGS-1843 awarded by the NASA Marshall Space 
Flight Center. The Government has certain rights in this 
invention. 
BACKGROUND OF THE INVENTION 
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FIG. 3 Coomassie stained protein gel (left) and corre- 	 etc., and determining the ratio of biologically active protein to 
sponding autoradiogram (right) of MtIA samples digested at 	 total protein. Generally, the specific activity as thus defined 
37° C. with Proteinase K. Abbreviations: Proteinase K (Prot 	 will be at least about 5% that of the native protein, usually at 
K), lithium dodecyl sulfate (LDS). 	 least about 10% that of the native protein, and may be about 
FIG. 4 Topology of TetA showing twelve transmembrane 5 25%, about 50%, about 90% or greater. 
segments. The largest cytoplasmic loop (M181-A213) is only 	 One aspect of the high yield is that the proteins are directly 
33 amino acids. 	 inserted into membranes during synthesis. Therefore the iso- 
FIG. 5 Coomassie stained protein gel (right) and corre- 	 lation of active membrane associated protein does not require 
sponding autoradiogram (left) of TetA samples digested at 	 the use of artificial lipo somes, or refolding of the protein. The 
25° C. with Proteinase K. Abbreviations: Proteinase K (Prot 10 protein may be directly isolated from the reaction mixture in 
K), lithium dodecyl sulfate (LDS). 	 any method that preserves the membrane association. Meth- 
FIG. 6 Tetracycline accumulation inside vesicles present 	 ods of protein purification that maintain membrane integrity 
during TetA or CAT protein expression. 	 are known in the art. Typically, mild detergents such as laurel 
FIG. 7 Schematic of the sucrose flotation assay. 	 glucosides or maltosides are used to distribute the properly 
FIG. 8 Distribution of radiolabeled MtIA in sucrose floata-  15 folded membrane spanning proteins into micelles containing 
tion assays. Vesicle-associated MtIA floats up to fraction 2, 	 one or only a few protein molecules. These micelles are then 
while aggregated MtIA remains at the bottom of the gradient 	 separated based on their protein cargoes to provide purified 
in fractions 6-8. 	 membrane spanning proteins (see Loll, P 7, J. of Structural 
FIG. 9 Distribution of radiolabeled TetA in sucrose flota- 	 Biology, 142:144-153; 2003), herein specifically incorpo- 
tion assays. Vesicle-associated TetA floats up to fraction 2, 20 rated by reference. 
while aggregated TetA remains at the bottom of the gradient 	 In some embodiments, the methods of the invention further 
in fractions 5-7. 6M urea is added to remove TetA that is 	 include providing signal recognition particles (SRP) to the 
non-specifically associated with the vesicles. 	 reaction. The particles may be exogenously produced, or 
FIG. 10. Distribution of radiolabeled AgpZ in sucrose 	 co-synthesized in the reaction mix. Docking protein (SR) 
floatation assays. Vesicle-associated AgpZ floats up to frac-  25 may also be included. 
tion 2, while aggregated AgpZ remains at the bottom of the 	 Activation of oxidative phosphorylation is obtained by a 
gradient in fractions 5-7. 	 combination of reaction conditions, which conditions may 
FIG. 11. Autoradiogram of AgpZ samples digested at 37° 
	
include, without limitation, the use of biological extracts 
C. with Proteinase K. Abbreviations: Proteinase K (Prot K), 	 derived from bacteria grown on a glucose containing 
lithium dodecyl sulfate (LDS). 	 30 medium; an absence of polyethylene glycol; and optimized 
FIG. 12. Rayleigh light scattering measurements monitor- 	 magnesium concentration. The system does not require the 
ing water transport out of vesicles in a hypertonic environ- 	 addition of commonly used secondary energy sources, which 
ment. Vesicles containing synthesized AgpZ show a faster 	 energy sources typically contain high energy phosphate 
rate of vesicle shrinkage than control vesicles obtained from 	 bonds, such as phosphoenolpyruvate, creatine phosphate, 
a control reaction in which an unrelated protein, chloram-  35 acetyl phosphate, glucose-6-phosphate, pyruvate or glyco- 
phenicol acetyl transferase (CAT), was produced. 	 lytic intermediates. The reaction may be further improved by 
employing ions and compounds in the cell-free reaction mix- 
DETAILED DESCRIPTION OF THE 	 ture that are commonly found in the E. coli cytoplasm. 
EMBODIMENTS 
40 	 DEFINITIONS 
High yield synthesis of membrane-associated proteins is 
accomplished by performing coupled transcription and trans- 	 It is to be understood that this invention is not limited to the 
lation reactions in a cell-free reaction, where membrane 	 particular methodology, protocols, cell lines, animal species 
vesicles are present, and where the reaction conditions pro- 	 or genera, and reagents described, as such may vary. It is also 
vide for in vitro activation of oxidative phosphorylation. The 45 to be understood that the terminology used herein is for the 
protein of interest is synthesized in a manner that allows 	 purpose of describing particular embodiments only, and is not 
co-translational folding and direct insertion of the nascent 	 intended to limit the scope of the present invention, which 
polypeptide into a membrane, thereby providing for folding 	 will be limited only by the appended claims. 
in a membrane environment. The method may further include 	 As used herein the singular forms "a", "and", and "the" 
the isolation of the synthesized protein in a membrane bound 50 include plural referents unless the context clearly dictates 
state. 	 otherwise. Thus, for example, reference to "a cell' includes a 
The methods of the invention provide for high yields of 	 plurality of such cells and reference to "the culture" includes 
active protein, which may be greater than the yield that can be 	 reference to one or more cultures and equivalents thereof 
achieved with in vivo expression systems. In one embodiment 	 known to those skilled in the art, and so forth. All technical 
of the invention, the yield of active membrane associated 55 and scientific terms used herein have the same meaning as 
protein is greater than the yield of the protein of interest in 	 commonly understood to one of ordinary skill in the art to 
vivo. In other aspects, the yield of active membrane-associ- 	 which this invention belongs unless clearly indicated other- 
ated protein is at least about 50 µg/ml of reaction mixture; at 	 wise. 
least about 100 µg/ml of reaction mixture; at least about 250 
	
The terms "desired protein" or "selected protein" are used 
µg/ml of reaction mixture; or more. 	 60 interchangeably and refer generally to any peptide or protein 
The methods of the present invention provide for mem- 	 having more than about 5 amino acids, which is membrane 
brane associated proteins that have biological activity com- 	 associated by virtue of a membrane inserted polypeptide. The 
parable to the native protein. One may determine the specific 	 polypeptides may be homologous to, or preferably, may be 
activity of a protein in a composition by determining the level 	 exogenous, meaning that they are heterologous, i.e., foreign, 
of activity in a functional assay, quantitating the amount of 65 to the bacteria from which the bacterial cell-free extract is 
protein present in a non-functional assay, e.g. immunostain- 	 derived, such as a human protein or a yeast protein produced 
ing, ELISA, quantitation on coomasie or silver stained gel, 	 in the bacterial cell-free extract. 
US 8,492,115 B2 
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Membrane Associated Proteins. 	 volume), more usually at least about 1%; and usually not 
Membrane proteins can be classified into two broad cat- 	 more than about 4%, more usually not more than about 2%. 
egories, integral (intrinsic) and peripheral (extrinsic), based 	 An example of such media is 2YTPG medium, however one 
on the nature of the membrane-protein interactions. For the 	 of skill in the art will appreciate that many culture media can 
purposes of the present invention, membrane associated pro-  5 be adapted for this purpose, as there are many published 
teins are typically integral membrane proteins, also called 	 media suitable for the growth of bacteria such as E. coli, using 
intrinsic proteins, which have one or more segments that are 	 both defined and undefined sources of nutrients (see Sam- 
embedded in the phospholipid bilayer. Most integral proteins 	 brook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular 
contain residues with hydrophobic side chains that interact 	 Cloning: A Laboratory Manual, 2" d edition. Cold Spring Har- 
with fatty acyl groups of the membrane phospholipids, thus io bor University Press, Cold Spring Harbor, N.Y. for examples 
anchoring the protein to the membrane. Most integral pro- 	 of glucose containing media). Alternatively, the culture may 
teins span the entire phospholipid bilayer. These transmem- 	 be grown using a protocol in which the glucose is continually 
brane proteins contain one or more membrane-spanning 	 fed as required to maintain a high growth rate in either a 
domains as well as domains, from four to several hundred 
	
defined or complex growth medium. 
residues long, extending into the aqueous medium on each 15 	 Another important change in the reaction mixture is the 
side of the bilayer. 	 substantial absence of polyethylene glycol (PEG). A conven- 
Some proteins are bound only to the membrane surface, 	 tional reaction mixture (for example, see Kim and Swartz, 
whereas others have one region buried within the membrane 	 2001) contains about 2% polyethylene glycol 8000. However 
and domains on one orboth sides of it. Protein domains on the 	 it is found that this diminishes the yield. Typically PEG will 
extracellular membrane surface are generally involved in 20 be present in not more than trace amounts, for example less 
cell-cell signaling or interactions. Domains within the mem- 	 than 0.1%, and may be less than 0.01%. In the present meth- 
brane, particularly those that form channels and pores, move 	 ods, the molecules spermidine and putrescine are used in the 
molecules across the membrane. Domains lying along the 	 place of PEG. Spermine or spermidine is present at a concen- 
cytosolic face of the membrane have a wide range of func- 	 tration of at least about 0.5 mM, usually at least about 1 mM, 
tions, from anchoring cytoskeletal proteins to the membrane 25 preferably about 1.5 mM, and not more than about 2.5 mM. 
to triggering intracellular signaling pathways. 	 Putrescine is present at a concentration of at least about 0.5 
G protein-coupled receptors are integral membrane pro- 	 mM, preferably at least about 1 mM, preferably about 1.5 
teins that possess seven membrane-spanning domains or 	 mM, and not more than about 2.5 mM. The spermidine and/or 
transmembrane helices. The extracellular parts of the recep- 	 putrescine may be present in the initial cell extract or may be 
tor can be glycosylated. These extracellular loops also con-  so separately added. 
tain two highly conserved cysteine residues which build dis- 	 The concentration of magnesium in the reaction mixture 
ulfide bonds to stabilize the receptor structure. Some seven 	 affects the overall synthesis. Often there is magnesium 
transmembrane helix proteins that resemble G proteins may 	 present in the cell extracts, which may then be adjusted with 
contain different functional groups, such as entire ion chan- 	 additional magnesium to optimize the concentration. Sources 
nels, within their protein. While in other types of receptors 35 of magnesium salts useful in such methods are known in the 
that have been studied ligands bind externally to the mem- 	 art. In one embodiment of the invention, the source of mag- 
brane, the ligands of G-protein-coupled receptors typically 	 nesium is magnesium glutamate. A preferred concentration 
bind within the transmembrane domain. 	 of magnesium is at least about 5 mM, usually at least about 10 
Another important class of membrane-associated proteins 	 mM, and preferably a least about 12 mM; and at a concentra- 
are ion channels. All ion channels are complexes of trans- 40 tion of not more than about 20 mM, usually not more than 
membrane proteins, sometimes they contain cytoplasmic 	 about 15 mM. Other changes that may enhance synthesis 
subunits, often they are glycosylated. Ion channels can be 	 include the omission of HEPES buffer and phosphoenol pyru- 
classified according to which chemical or physical modulator 	 vate from the reaction mixture. 
controls their gating activity. Thus we have different groups 	 The system can be run under aerobic and anaerobic condi- 
of channels, including: ligand gated channels/neurotransmit-  45 tions. Oxygen may be supplied, particularly for reactions 
ters; voltage gated channels/transmembrane potential (elec- 	 larger than 15 µl, in order to increase synthesis yields. The 
tric field); second messenger gated channels/nucleotides, 	 headspace of the reaction chamber can be filled with oxygen; 
G-proteins; mechano sensitive channels/osmotic pressure or 	 oxygen may be infused into the reaction mixture; etc. Oxygen 
membrane curvature; gap junctions, porins/not gated. Chan- 	 can be supplied continuously or the headspace of the reaction 
nels are also ion selective. They can discriminate between 50 chamber can be refilled during the course of protein expres- 
size and charge of the permeant molecule. 	 sion for longer reaction times. Other electron acceptors, such 
In vitro synthesis, as used herein, refers to the cell-free 	 as nitrate, sulfate, or fumarate may also be supplied in con- 
synthesis of polypeptides in a reaction mix comprising bio- 	 junction with preparing cell extracts so that the required 
logical extracts and/or defined reagents. The reaction mix will 	 enzymes are active in the cell extract. 
comprise a template for production of the macromolecule, 55 	 It is not necessary to add exogenous cofactors for activation 
e.g. DNA, mRNA, etc.; monomers for the macromolecule to 	 of oxidative phosphorylation. Compounds such as nicotina- 
be synthesized, e.g. amino acids, nucleotides, etc., and such 	 mide adenine dinucleotide (NADH), NAD', or acetyl-coen- 
co-factors, enzymes and other reagents that are necessary for 	 zyme A may be used to supplement protein synthesis yields 
the synthesis, e.g. ribosomes, tRNA, polymerases, transcrip- 	 but are not required. Addition of oxalic acid, a metabolic 
tional factors, etc. Such synthetic reaction systems are well- 60 inhibitor of phosphoenolpyruvate synthetase (Pps), may be 
known in the art, and have been described in the literature. 	 beneficial in increasing protein yields, but is not necessary. 
The cell free synthesis reaction may be performed as batch, 	 The template for cell-free protein synthesis can be either 
continuous flow, or semi-continuous flow, as known in the art. 	 mRNA or DNA, preferably a combined system continuously 
The Cytomimrm environment for synthesis utilizes cell 	 generates mRNA from a DNA template with a recognizable 
extracts derived from bacterial cells grown in medium con-  65 promoter. Either endogenous RNA polymerase is used, or an 
taining glucose and phosphate, where the glucose is present 	 exogenous phage RNA polymerase, typically T7 or SP6, is 
initially at a concentration of at least about 0.25% (weight/ 	 added directly to the reaction mixture. Alternatively, mRNA 
US 8,492,115 B2 
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can be continually amplified by inserting the message into a 
template for QB replicase, an RNA dependent RNA poly-
merase. Purified mRNA is generally stabilized by chemical 
modification before it is added to the reaction mixture. 
Nucleases can be removed from extracts to help stabilize 
mRNA levels. The template can encode for any particular 
gene of interest. 
Other salts, particularly those that are biologically relevant, 
such as manganese, may also be added. Potassium is gener-
ally present at a concentration of at least about 50 mM, and 
not more than about 250 mM. Ammonium may be present, 
usually at a concentration of not more than 200 mM, more 
usually at a concentration of not more than about 100 mM. 
Usually, the reaction is maintained in the range of about pH 
5-10 and a temperature of about 20°-50° C.; more usually, in 
the range of about pH 6-9 and a temperature of about 25'-40' 
C. These ranges may be extended for specific conditions of 
interest. 
Metabolic inhibitors to undesirable enzymatic activity may 
be added to the reaction mixture. Alternatively, enzymes or 
factors that are responsible for undesirable activity may be 
removed directly from the extract or the gene encoding the 
undesirable enzyme may be inactivated or deleted from the 
chromosome. 
Vesicles are added to the reaction mix. Vesicles may puri-
fied from the organism from which the extract is derived (see 
Muller and Blobel (1984) "In vitro translocation of bacterial 
proteins across the plasma membrane of Escherichia coli", 
PNAS 81:7421-7425); or isolated from any other suitable 
cell, e.g. mammalian cells including cells from the species of 
target protein; or synthetic. Vesicles are typically added at a 
concentration of 0.1 to 5 mg/ml lipids, more preferably about 
0.4 to 2.5 mg/ml. Vesicles may be purified by sucrose density 
gradient centrifugation or by other means known in the art. 
Vesicle preparation methods include, without limitation: 
homogenization, French press, extrusion, freeze/thaw, soni-
cation, osmotic lysis, lysozyme/EDTA treatment, and the 
like. Other components that affect membrane protein inser-
tion or folding may be added to the cell-free reaction mixture, 
including SRP, Ffh, 4.5S RNA, FtsY, and SecA. 
Signal Recognition Particle. 
Co-translational targeting of secretory and membrane pro-
teins to the prokaryotic plasma membrane or eukaryotic 
endoplasmic reticulum is mediated by a ribonucleoprotein 
complex, the signal recognition particle (SRP), and its mem-
brane-associated receptor (SR). SRP binds to signal 
sequences of nascent proteins as they emerge from the exit 
tunnel of the ribosome. The resulting targeting complex, 
composed of the SRP and the ribosome—nascent chain com-
plex (RNC), then docks with the SR in a GTP-dependent 
manner. Passing through a complex series of conformational 
states, SRP and SR deliver the RNC to the translocon, which 
in turn mediates protein translocation across or integration 
into the membrane. As translocation proceeds, the signal 
sequence may be cleaved by signal protease and the polypep-
tide released into the ER lumen. Alternatively, the protein can 
insert into the membrane to form a membrane spanning pro-
tein. 
The bacterial SRP has a simple composition as compared 
to its eukaryotic counterpart. It contains only a single protein 
homologous to SRP54 (termed Ffh) and a single RNA mol-
ecule, between 80 and 200 nts in size, e.g. a I I0-nucleotide 
4.5S RNA in E. coli. In bacteria and archaea, SRs are single-
subunit proteins, also named FtsY. Bacterial SRs are periph-
erally associated with membranes. 
The SRP and docking protein (SR) are optionally included 
in the reaction mix for the methods of the invention. These 
8 
may be provided through co-expression of the components in 
the reaction mix, or through exogenous addition. Where the 
components are provided by co-expression, a vector encod-
ing the Ffh protein and the 4.5S RNA are provided. The FtsY 
5 protein may also be co-expressed. Co-expression may be 
sequential or simultaneous. Alternatively, these components 
may be produced and isolated from in vitro or in vivo expres-
sion, and added to the mixture; or may be over-produced in 
the bacteria from which the extracts are derived. 
10 	 Folding, as used herein, refers to the process of forming the 
three-dimensional structure of polypeptides and proteins, 
where interactions between amino acid residues act to stabi- 
lize the structure. Non-covalent interactions are important in 
15 determining structure, and the effect of membrane contacts 
with the protein are important for the correct structure. For 
naturally occurring proteins and polypeptides or derivatives 
and variants thereof, the result of proper folding is typically 
the arrangement that results in optimal biological activity, and 
20 can conveniently be monitored by assays for activity, e.g. 
ligand binding, enzymatic activity, etc. 
In some instances, for example where the desired product 
is of synthetic origin, assays based on biological activity will 
be less meaningful. The proper folding of such molecules 
25 may be determined on the basis of physical properties, ener-
getic considerations, modeling studies, and the like. 
The synthesis of membrane-associated protein may be fol-
lowed by direct isolation of the active, membrane associated 
forms, i.e. in the absence of refolding or post-translational 
30 introduction of membranes. The separation procedure will 
utilize conditions that maintain membrane integrity, as is 
known in the art. 
Separation procedures of interest include affinity chroma-
tography. Affinity chromatography makes use of the highly 
35 specific binding sites usually present in biological macromol-
ecules, separating molecules on their ability to bind a particu-
lar ligand. Covalent bonds attach the ligand to an insoluble, 
porous support medium in a manner that overtly presents the 
ligand to the protein sample, thereby using natural biospecific 
40 binding of one molecular species to separate and purify a 
second species from a mixture. Antibodies are commonly 
used in affinity chromatography. Preferably a microsphere or 
matrix is used as the support for affinity chromatography. 
Such supports are known in the art and are commercially 
45 available, and include activated supports that can be coupled 
to the linker molecules. For example, Affi-Gel supports, 
based on agarose or polyacrylamide are low pressure gels 
suitable for most laboratory-scale purifications with a peri-
staltic pump or gravity flow elution. Affi-Prep supports, based 
50 on a pressure-stable macroporous polymer, are suitable for 
preparative and process scale applications. 
Proteins may also be separated by ion exchange chroma-
tography, and/or concentrated, filtered, dialyzed, etc., using 
methods known in the art. 
55 
Methods for Synthesis 
The reactions may utilize a large scale reactor, small scale, 
or may be multiplexed to perform a plurality of simultaneous 
60 syntheses. Continuous reactions will use a feed mechanism to 
introduce a flow of reagents, and may isolate the end-product 
as part of the process. Batch systems are also of interest, 
where additional reagents may be introduced to prolong the 
period of time for active synthesis. A reactor may be run in 
65 any mode such as batch, extended batch, semi-batch, semi-
continuous, fed-batch and continuous, and which will be 
selected in accordance with the application purpose. 
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The reactions maybe of any volume, either in a small scale, 
usually at least about 1 ld and not more than about 15 µl, or in 
a scaled up reaction, where the reaction volume is at least 
about 15 µl, usually at least about 50 µl, more usually at least 
about 100 µl, and may be 500 µl, 1000 µl, or greater. In most 5 
cases, individual reactions will not be more than about 10 ml, 
although multiple reactions can be run in parallel. However, 
in principle, reactions may be conducted at any scale as long 
as sufficient oxygen (or other electron acceptor) is supplied 
when needed. 10 
In addition to the above components such as cell-free 
extract, genetic template, and amino acids, materials specifi-
cally required for protein synthesis may be added to the 
reaction. These materials include salt, folinic acid, cyclic 15 
AMP, inhibitors for protein or nucleic acid degrading 
enzymes, inhibitors or regulators of protein synthesis, adjust-
ers of oxidation/reduction potential(s), non-denaturing sur-
factants, buffer components, spermine, spermidine, 
putrescine, etc. 20 
The salts preferably include potassium, magnesium, and 
ammonium salts (e.g. of acetic acid or sulfuric acid). One or 
more of such salts may have amino acids as a counter anion. 
There is an interdependence among ionic species for optimal 
concentration. These ionic species are typically optimized 25 
with regard to protein production. When changing the con-
centration of a particular component of the reaction medium, 
that of another component may be changed accordingly. For 
example, the concentrations of several components such as 
nucleotides and energy source compounds may be simulta- 30 
neously adjusted in accordance with the change in those of 
other components. Also, the concentration levels of compo-
nents in the reactor may be varied over time. The adjuster of 
oxidation/reduction potential may be dithiothreitol, ascorbic 35 
acid, glutathione and/or their oxidized forms. 
In a semi-continuous operation mode, the outside or outer 
surface of the membrane is put into contact with predeter-
mined solutions that are cyclically changed in a predeter-
mined order. These solutions contain substrates such as 40 
amino acids and nucleotides. At this time, the reactor is oper-
ated in dialysis, diafiltration batch or fed-batch mode. A feed 
solution may be supplied to the reactor through the same 
membrane or a separate injection unit. Synthesized protein is 
accumulated in the reactor, and then is isolated and purified 45 
according to the usual method for protein purification after 
completion of the system operation. Vesicles containing the 
product may also be continuously isolated, for example by 
affinity adsorption from the reaction mixture either in situ or 
in a circulation loop as the reaction fluid is pumped past the 50 
adsorption matrix. 
Where there is a flow of reagents, the direction of liquid 
flow can be perpendicular and/or tangential to a membrane. 
Tangential flow is effective forrecyclingATP and forprevent-
ing membrane plugging and may be superimposed on per- 55 
pendicular flow. Flow perpendicular to the membrane may be 
caused or effected by a positive pressure pump or a vacuum 
suction pump or by applying transmembrane pressure using 
other methods known in the art. The solution in contact with 
the outside surface of the membrane may be cyclically 60 
changed, and may be in a steady tangential flow with respect 
to the membrane. The reactor may be stirred internally or 
externally by proper agitation means. 
During protein synthesis in the reactor, the protein isolat- 
ing means for selectively isolating the desired protein may 65 
include a unit packed with particles coated with antibody 
molecules or other molecules immobilized with a component 
10 
for adsorbing the synthesized, desired protein. Preferably, the 
protein isolating means comprises two columns for alternat-
ing use. 
The amount of protein produced in a translation reaction 
can be measured in various fashions. One method relies on the 
availability of an assay which measures the activity of the 
particular protein being translated. An example of an assay 
for measuring protein activity is a luciferase assay system, or 
chloramphenical acetyl transferase assay system. These 
assays measure the amount of functionally active protein 
produced from the translation reaction. Activity assays will 
not measure full length protein that is inactive due to 
improper protein folding or lack of other post translational 
modifications necessary for protein activity. 
Another method of measuring the amount of protein pro-
duced in coupled in vitro transcription and translation reac-
tions is to perform the reactions using a known quantity of 
radiolabeled amino acid such as 35 S-methionine, 3 H-leucine 
or 14C-leucine and subsequently measuring the amount of 
radiolabeled amino acid incorporated into the newly trans-
lated protein. Incorporation assays will measure the amount 
of radiolabeled amino acids in all proteins produced in an in 
vitro translation reaction including truncated protein prod-
ucts. The radiolabeled protein may be further separated on a 
protein gel, and by autoradiography confirmed that the prod-
uct is the proper size and that secondary protein products have 
not been produced. 
Kits for the practice of the subject methods may also be 
provided. Such kits may include bacterial extracts for protein 
synthesis, buffers appropriate for reactions where oxidative 
phosphorylation is activated, and vesicles. Kits may also 
include vectors for protein synthesis, including vectors for 
expression of SRP and SR proteins; where the vectors may 
comprise promoter systems useful in bacterial extracts. 
The following examples are put forth so as to provide those 
of ordinary skill in the art with a complete disclosure and 
description of how to make and use the subject invention, and 
are not intended to limit the scope of what is regarded as the 
invention. Efforts have been made to ensure accuracy with 
respect to the numbers used (e.g. amounts, temperature, con-
centrations, etc.) but some experimental errors and deviations 
should be allowed for. Unless otherwise indicated, parts are 
parts by weight, molecular weight is average molecular 
weight, temperature is in degrees centigrade; and pressure is 
at or near atmospheric. 
EXPERIMENTAL 
Example 1 
The protein synthesis reaction for these examples uses the 
Cytomim'TM protocol described in WO 2004/016778, herein 
specifically incorporated by reference, with slight modifica-
tions. The components of this reaction include 13.3 µg/mL 
template plasmid, 1.2 mM AMP, 0.86 mM CMP, 0.86 mM 
GMP, 0.86 mM UMP, 34 µg/mL folinic acid, 170.6 µg/mL E. 
coli tRNA mixture, 2 mM each of 20 unlabeled amino acids, 
0.33 mM nicotinamide adenine dinucleotide, 0.27 mM coen-
zyme A, 1 mMputrescine, 1.5 mM spermidine, 4 mM sodium 
oxalate, 1 mM dithiothreitol, 10 mM ammonium glutamate, 
130 mM potassium glutamate, 8 mM magnesium glutamate, 
10 mM potassium phosphate pH 7.2, 12 µM [ 14C] -leucine, 
0.1 mg/mL T7 RNA polymerase, 0.24 volumes of E. coli S30 
extract, and 0.41 volumes of vesicle solution (detailed 
below). T7 RNA polymerase is prepared as described by 
Grodberg and Dunn (7 of Bacteriology, 170:1245-1253; 
1988). E. coli S30 extract is prepared from the strain KC6 
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(A19 AtonA AtnaA AspeA AendA AsdaA AsdaB AgsbA 
met') (Calhoun and Swartz, Biotechnology Progress 2005. 
21(4): p. 1146-53) grown according to Zawada, et al. in 
Fermentation Biotechnology, B. Saba, Editor. 2003, Ameri-
can Chemical Society: Washington, D.C. p. 142-156, and 5 
prepared according to Jewett, et al. in Gene Cloning and 
Expression Technologies, M. Weiner and Q. Lu, Editors. 
2002, Eaton Publishing: Westborough, Mass. p. 391-411. 
The vesicle solution is prepared using a method adapted 
from Muller and Blobel (1984) Proc Natl Acad Sci USA, io 
81(23): p. 7421-5, and Osborn, et al (1972) J Biol Chem, 
1972. 247(12): p. 3962-72. KC6 cells are resuspended and 
washed in 20 mM Tris-HCl pH 8.0, 1 mM EDTA. The final 
cell pellet is resuspended in 1 mL of the same buffer per gram 
of cells and incubated on ice with 0.2 mg/mL of lysozyme for 15 
15 min. After incubation, the cell solution is passed through 
an Avestin homogenizer three times at 20000 psi. Unbroken 
cells and debris are removed by two centrifugations at 
30000xg for 20 min each. Then the vesicles are collected by 
ultracentrifugation (154000xg, 1.5 hr), and pelleted again 20 
through 0.5 mLlg C,,, of a solution containing 250 mM 
sucrose in buffer H (20 mM HEPES-KOH pH 7.5, 1 mM 
DTT, 5 mM EDTA) at 231000xg for 1 hr. These crudely 
purified vesicles are resuspended in 20% (w/w) sucrose in 
buffer Hand loaded on top of a step gradient containing layers 25 
of 50%, 45%, 40%, 35%, 30%, and 25% (w/w) sucrose in 
buffer H. After ultracentrifugation for 24 hrs at I I4000xg, the 
fractions containing inner membrane vesicles (as detailed in 
Spencer et al. (1974) J Bacteriol, 117(3): p. 947-53, or Lan-
gley et al. (1982) J Bacteriol, 152(3): p. 1033-41) are col- 30 
lected. These vesicles are pelleted by ultracentrifugation at 
231,OOOxg for 1 hr and finally resuspended to high concen-
tration (1-2 mg/mL) in 20 mM HEPES-KOH pH 7.2, 60 mM 
KCl, 1 mM DTT. 
The membrane proteins mannitol permease (MtIA) and the 35 
tetracycline pump (TetA) were synthesized by the methods of 
the invention. The plasmids pK7MtIA and pK7TetA, respec-
tively, were used as templates encoding the genes under the 
control of T7 promoters. 
After 6 hrs of synthesis at 37° C., the synthesized protein 40 
was quantified by measuring TCA-precipitable radioactivity 
using a liquid scintillation counter. FIG. 1 shows the total 
amount of MtIA and TetA produced during the cell-free reac-
tion. Before further analysis, the reaction was crudely puri-
fied by dialysis with a 100 kDa MWCO dialysis bag against 45 
500-1000 volumes of 10 mM Tris-HCl pH 8.0, 100 mM KCl, 
exchanged three times for at least 3 hours each time. The 
results in FIG.1 show that virtually all the synthesized protein 
is retained during dialysis. 
To determine if the synthesized protein was folded prop- 50 
erly in the vesicle membranes, we exposed the dialyzed reac-
tion mixture to 0.2 µg/ltL of the non-specific protease, Pro-
teinase K. Portions of the membrane protein that are not 
embedded in the membrane such as cytoplasmic domains 
or large loops between transmembrane segments are 55 
degraded more quickly by the protease as compared with 
segments within the membrane or in the vesicle interior. 
Thus, by observing the protein fragments generated by Pro-
teinase K digestion over time, we can verify whether the 
protein has the expected topology that corresponds with 60 
proper folding. 
MtIA is well suited forprotease digestion analysis because 
it contains a large cytoplasmic domain (FIG. 2a) as well as a 
large cytoplasmic loop (FIG. 2b). FIG. 3 shows digested 
MtIA after incubation with Proteinase K at 37° C. for 0 to 60 65 
min. During the early time points, a distinct band of approxi-
mately 30 kDa is formed. This corresponds well with a frag- 
ment containing only the six transmembrane segments, after 
degradation of the large cytoplasmic domain. As the digestion 
reaction proceeds, the 30 kDa band diminishes in favor of a 17 
kDa band. This 17 kDa band is comparable to the expected 
fragment containing four transmembrane segments, obtained 
after digestion of the large 89-amino acid cytoplasmic loop. If 
the reaction is performed in the presence of lithium dodecyl 
sulfate (LDS) detergent which dissolves membranes, the 
MtIA bands are no longer protected from digestion; indicat-
ing that the protected bands are dependent on the presence of 
intact vesicle membranes. Thus, the observed band pattern 
demonstrates that a significant portion of the MtIA is properly 
folded in the vesicle membranes. 
A similar analysis was performed with TetA. The topology 
of TetA, shown in FIG. 4, does not contain any large cyto-
plasmic domains or loops. Therefore, we focused on protec-
tion of the full-length TetA. FIG. 5 shows the band profile 
obtained after incubation with Proteinase K at 25° C. Even 
after 60 min, a significant fraction of full-length TetA is still 
present in the vesicles. However, if the membranes are dis-
solved with LDS detergent, the TetA is no longer protected 
from digestion. Thus, it appears that the TetA is embedded 
into the vesicle membranes. 
To further demonstrate that the TetA is properly folded, 
activity of the TetA protein was assayed. TetA is a proton-
antiporter, using a proton gradient to drive transport of a 
metal-tetracycline complex across the membrane. To assay 
for TetA activity, first the TetA-containing vesicles were 
exposed to 13.3 mM NADH for 1 min at 37° C. in order to 
generate a proton gradient across the vesicle membrane. 10 
µM [3 H]-tetracycline and 0.5 mM cobalt chloride were then 
added, and the reaction was further incubated for the times 
indicated in FIG. 6. The reactions are finally filtered and 
washed through a 30K molecular weight centrifugal filter to 
separate vesicle-associated tetracycline from free tetracy-
cline in solution. FIG. 6 shows that more tetracycline accu-
mulates within vesicles containing TetA, as compared to con-
trol vesicles obtained from a cell-free reaction producing the 
unrelated soluble protein chloramphenicol acetyl transferase 
(CAT). The control vesicles show tetracycline accumulation 
of approximately 3-13 µM within the vesicles, which is con-
sistent with equilibrium driven diffusion of tetracycline 
across the lipid membrane. The vesicles containing TetA, 
however, are able to accumulate tetracycline even against a 
tetracycline concentration gradient, indicating that a signifi-
cant portion of TetA is properly folded and active in the 
vesicles. 
To quantify the amount of protein inserted into the vesicles, 
the dialyzed cell-free reactions were subjected to a sucrose 
flotation assay. The dialyzed reaction is mixed with a dense 
sucrose solution and loaded at the bottom of a three step 
sucrose gradient (see FIG. 7). The densities of the layers are 
chosen such that, after ultracentrifugation (16 hrs, 237000x 
g), the misfolded protein aggregates (with density p-1.3 
g/mL) stay in the bottom layer while the lighter vesicles 
(p-1.13-1.25 g/mL, depending on how much protein has 
been inserted) float to the interface above the second layer. 
FIG. 8 shows the distribution of radiolabeled MtIA after 
sucrose floatation analysis. 6 M urea has been added through-
out the gradients to reduce non-specific association of the 
synthesized protein with membranes. When vesicles are 
present in the reaction, we see that 20% of the synthesized 
MtIA is associated with the vesicles (fraction 2). This asso-
ciation disappears when the vesicles are not added to the 
protein synthesis reaction, as indicated by the retention of 
aggregated MtIA in the lower fractions (fractions 6-8). The 
amount of MtIA shown inserted into vesicles corresponds to 
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an overall yield of 60 µg of inserted MtIA per mL of cell-free 
reaction, approximately 30 times the typical in vivo yields for 
MtIA (<2 µg/mL). 
Even higher yields were obtained for TetA. FIG. 9 shows 
sucrose floatation profiles for reactions producing TetA. In 
the presence of vesicles, over 60% of the synthesized TetA is 
associated with the vesicles (fraction 2). The addition of 6M 
urea only slightly reduces this value, indicating that the TetA 
is specifically associated. When the vesicles are not added to 
the synthesis reaction, the TetA remains aggregated and local-
izes in fractions 5-7 of the sucrose gradient. The amount of 
TetA shown inserted into vesicles corresponds to an overall 
yield of 440 µg of inserted TetA per mL of cell-free reaction, 
approximately 300 times the typical in vivo yields for TetA 
(1-1.5 wg/mL). 
These data demonstrate that high yields of membrane pro-
teins are synthesized by the methods of the invention, and the 
synthesized protein is inserted into vesicles and properly 
folded. 
Example 2 
TetA Activity Assay 
The TetA activity assay is performed similarly to that 
described inYamaguchi, et al (1990) J Biol Chem, 265(9): p. 
4809-13. TetA is a proton-antiporter, catalyzing the transport 
of a metal-tetracycine complex out of the cytoplasm using the 
cell's natural proton gradient as the driving force. 
To assay for TetA activity, a proton gradient is generated 
across the vesicle membrane by exposing the TetA-contain-
ing vesicles to 13.3 mM NADH at 37° C. for a fixed amount 
of time. The generated pH gradient is quantified using a 
self-quenching, pH-sensitive fluorescent dye, such as quina-
crine (Yamaguchi et al., (199 1) FEBS Lett, 282(2): p. 415-8.) 
This dye is membrane permeable in its neutral state, but 
becomes protonated at low pH causing it to be preferentially 
trapped inside the vesicles after the gradient has been gener-
ated. Since the dye is self-quenching, the amount of dye 
trapped in the vesicles is indicated by a overall drop in fluo-
rescence signal, thereby giving a quantifiable measure of the 
pH inside the vesicles. 
After generation of the pH gradient, 10 µM [3 H]-tetracy-
cline and 0.5 mM cobalt chloride is then added, and the 
reaction is further incubated at 37° C. At specified time inter-
vals, the transported tetracycline is measured by collecting 
the vesicles and washing using a 30 kD molecular weight 
centrifugal filter which separates vesicle-associated tetracy-
cline from free tetracycline in solution. The radioactive tet-
racycline remaining on the filters can then be quantified using 
a liquid scintillation counter. By combining this data with the 
measurements of inserted protein from sucrose flotation 
assays, the rate of tetracycline transport per TetA molecule 
per unit pH gradient is calculated. 
To determine if cell-free produced TetA is fully active, the 
activity data is compared to vesicles made from E. coli strain 
KC6 expressing TetA in vivo. The activity assay is performed 
with these vesicles as described above. In order to quantify 
the number of TetA molecules in the cell-free vesicles, a 
fifteen amino acid tag is added to the TetA protein which is 
readily biotinylated by birA ligase (Avidity, LLC). After 
biotinylation, the vesicles are expo sed to radiolabeled strepta-
vidin. By measuring the amount of bound streptavidin, the 
corresponding amount of TetA contained in the vesicles is 
calculated.  
5 	 Mannitol transport by MtIA is a PEP-driven process 
involving two other cytoplasmic enzymes, HPr (heat stable, 
histidyl phosphorylatable protein) and PTS Enzyme I. To 
assay for MtIA activity, the vesicles are preloaded with man-
nitol. This can be done either (a) by homogenizing cells in 
10 buffer containing mannitol during preparation of the vesicle 
solution before cell-free synthesis of MtIA or (b) by extruding 
MtIA-containing vesicles after the cell-free reaction in buffer 
containing mannitol. After a crude purification by dialysis in 
15 a 100 kDa MWCO dialysis bag, any residual HPr (9 kDa) or 
Enzyme I (63 kDa) carried over from the cell extract is 
removed. 
Known amounts of purified HPr, Enzyme I, and PEP are 
added to the vesicles to initial transport of MtIA out of the 
20 vesicles. After incubation at 37° C. for specified time inter-
vals, the vesicles are collected and washed using a 30 kD 
molecular weight centrifugal filter which separates vesicle-
encapsulated mannitol from free mannitol in solution. The 
encapsulated mannitol (afterreleaseby addition of detergent) 
25 or free mannitol is quantified by HPLC. Taking this data with 
the measurement of inserted protein from sucrose flotation 
assays, the rate of transport per MtIA molecule is calculated. 
To determine if our cell-free produced MtIA is fully active, 
similar techniques as described above for TetA to produce 
30 vesicles containing known amounts of in vivo produced MtIA 
are used. 
Example 4 
35 	 Expression of Amaporin 
Using the methods described above, the membrane pro-
tein, aquaporin Z (AgpZ), is produced in high yields and 
inserted directly into E. coli inner membrane vesicles without 
40 the use of detergents or refolding steps. 
AgpZ is a 24 kDa with six transmembrane segments that 
serves as a water-specific channel in the inner membrane of E. 
coli (Ringler, P., et al., Structure of the water channel AgpZ 
from Escherichia coli revealed by electron crystallography. 
45 Journal of Molecular Biology, 1999. 291(5): p. 1181-1190). 
AgpZ was produced in a cytomim-based cell-free reaction, 
as described above, supplemented with up to 0.6 mg/mL 
(based on lipid content) of purified inner membrane vesicles. 
These reactions yielded about 650-800 µg/mL of total AgpZ. 
5o To determine how much of this protein is associated with 
vesicles, we used sucrose floatation to separate the vesicles 
from any aggregatedAgpZ. FIG. 10 shows the distribution of 
AgpZ in the sucrose gradient. The vesicles, having lower 
density, float up through the gradient (fraction 2) while the 
55 denser aggregates stay at the bottom (fractions 5-7). 6M urea 
is also present throughout each gradient to minimize non-
specific association of unfolded protein with the vesicles. 
When vesicles are supplemented in the cell-free reaction, 
about 50% of the AgpZ is recovered in the vesicle fraction. 
60 In contrast, a reaction in which vesicles are not added 
shows virtually all of theAgpZ remaining at the bottom of the 
gradient, presumably in an aggregated form. These results 
show nearly 400 µg/mL of vesicle-associated AgpZ can be 
produced in the natural vesicles. This is over 150 times the 
65 typical yields obtained when AgpZisoverexpressedinE.coli 
(Borgnia, M. J., et al., Functional reconstitution and charac-
terization ofAgpZ, the E. coli water channel protein. Journal 
14 
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of Molecular Biology, 1999.291(5):p. 1169-1179). The yield 
of vesicle-associated AgpZ in our cell-free system is similar 
to that seen with TetA. 
To determine if the vesicle-associated AgpZ is properly 
inserted, we subjected the protein to protease digestion. Prop-
erly folded AgpZ is known to be resistant to the protease 
Proteinase K, presumably protected by the surrounding lipid 
membrane. FIG. 12 shows an autoradiogram in which radio-
labeled AgpZ is exposed to the protease for increasing dura-
tions. Even after one hour, a significant fraction of the full-
lengthAgpZ remains. In contrast, when the lipid membranes 
are dissolved using LDS detergent, the AgpZ is no longer 
protected, showing nearly complete degradation by 15 min. 
These results suggest that the associated AgpZ is properly 
inserted into the vesicle membrane. 
In addition to protease digestion, we also measured the 
activity of the produced AgpZ by measuring water transport 
using stopped-flow static light scattering (Haines, T. H., 
Water Transport across Biological-Membranes. Febs Letters, 
1994. 346(1): p. 115-122). Vesicles containing the synthe-
sized AgpZ are extruded through a 50 nm membrane. The 
vesicle solution (0.05 mg/mL lipid basis) is then simulta-
neously injected into the flow chamber along with a 150 mM 
sucrose solution. The hypertonic environment causes the 
vesicles to shrink with time. The shrinkage rate can be moni-
tored by measuring the amount of Rayleigh light scattering 
that results (FIG. 12). Vesicles containing synthesized AgpZ 
show much faster shrinkage rates (time constant ti=7 ms) than 
control vesicles in which an unrelated protein was produced 
(time constant ti=20 ms). From this data, we calculate a spe-
cific activity of 3.7x10-14 cm3/sec/monomer which matches 
the specific activities measured for in vivo produced AgpZ 
(2-10x10-14 cm3/sec/monomer (Pohl, P., et al., Highly selec-
tive water channel activity measured by voltage clamp: 
Analysis of planar lipid bilayers reconstituted with purified 
AgpZ. Proceedings of the National Academy of Sciences of 
the United States of America, 2001. 98(17): p. 9624-9629). 
Thus, the AgpZ produced in our cell-free system is the same 
as that produced in vivo. 
It is to be understood that this invention is not limited to the 
particular methodology, protocols, cell lines, animal species 
or genera, constructs, and reagents described, as such may, of 
course, vary. It is also to be understood that the terminology 
used herein is for the purpose of describing particular 
embodiments only, and is not intended to limit the scope of 
the present invention, which will be limited only by the 
appended claims. 
Unless defined otherwise, all technical and scientific terms 
used herein have the same meaning as commonly understood 
to one of ordinary skill in the art to which this invention 
belongs. Although any methods, devices and materials simi-
lar or equivalent to those described herein can be used in the 
practice or testing of the invention, the preferred methods, 
devices and materials are now described. 
All publications mentioned herein are incorporated herein 
by reference for the purpose of describing and disclosing, for 
example, the cell lines, constructs, and methodologies that are 
described in the publications, which might be used in con-
nection with the presently described invention. The publica-
tions discussed above and throughout the text are provided 
solely for their disclosure prior to the filing date of the present 
application. Nothing herein is to be construed as an admission 
that the inventors are not entitled to antedate such disclosure 
by virtue of prior invention. 
What is claimed is: 
1. A reaction mix for synthesis of membrane associated 
polypeptides in a cell-free in vitro reaction: 
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where the reaction mixture comprises vesicles for direct 
insertion of said polypeptide, said vesicles added to a 
concentration of at least 0.4 mg/ml, where the reaction 
mix further comprises less than 0. 1% polyethylene gly- 
5 col, and wherein the reaction conditions provide for 
in-vitro activation of oxidative phosphorylation and 
where said membrane protein is synthesized at a con-
centration greater than that achieved in-vivo. 
2. The reaction mix of claim 1, wherein said reaction mix-
10 ture produces at least about 50 mg/ml of membrane associ-
ated polypeptide. 
3. The reaction mix of claim 1, wherein said reaction mix-
ture comprises signal recognition particles (SRP). 
15 	 4. The reaction mix of claim 3, wherein said reaction mix- 
ture further comprises FtsY protein. 
5. The reaction mix of claim 1, wherein said reaction mix 
comprises an extract from E. coli grown in glucose containing 
medium. 
20 	 6. The reaction mix of claim 5, wherein said E. coli are 
grown in glucose and phosphate containing medium. 
7. The reaction mix of claim 1, wherein said reaction mix 
comprises magnesium at a concentration of from about 5 mM 
to about 20 mM. 
25 	 8. The reaction mix according to claim 7, wherein said 
reaction mix comprises less than 0.01% polyethylene glycol. 
9. The reaction mix of claim 8, wherein said reaction mix 
comprises one or more of spermine, spermidine and 
putrescine. 
30 	 10. A reaction mix for synthesis of integral membrane 
associated polypeptides in a cell-free in vitro reaction com-
prising: 
an extract from bacterial cells; components of polypeptide 
35 synthesis machinery; a template for transcription of 
mRNA and/or translation of an integral membrane pro-
tein; monomers for synthesis of said mRNA and/or 
polypeptides; and co-factors, enzymes and other 
reagents necessary for said transcription and/or transla- 
40 tion; and vesicles added to a concentration of at least 0.4 
mg/ml lipids, wherein the reaction mix produces at least 
50 mg/ml of said integral membrane associated 
polypeptides. 
11. The reaction mix according to claim 10, wherein said 
45 reaction mixture produces at least 100 mg/ml of membrane 
associated polypeptide. 
12. The reaction mix according to claim 10, wherein said 
reaction mixture comprises signal recognition particles 
(SRP). 
50 	 13. The reaction mix according to claim 12, wherein said 
reaction mixture further comprises FtsY protein. 
14. The reaction mix according to claim 10, wherein said 
reaction mix comprises an extract from E. coli grown in 
glucose containing medium. 
55 	 15. The reaction mix according to claim 10, wherein said E. 
coli are grown in glucose and phosphate containing medium. 
16. The reaction mix according to claim 10, wherein said 
reaction mix comprises magnesium at a concentration of 
from about 5 mM to about 20 mM. 
60 	 17. The reaction mix according to claim 10, wherein said 
reaction mix comprises less than 0.01% polyethylene glycol. 
18. The reaction mix according to claim 10, wherein said 
reaction mix comprises one or more of spermine, spermidine 
and putrescine. 
65 	 19. The reaction mix according to claim 10, wherein the 
vesicles are purified prior to addition to the reaction mixture. 
